Analysts Are Neutral on Top Healthcare Stocks: Amgen (AMGN), Treace Medical Concepts (TMCI)
Analysts fell to the sidelines weighing in on Amgen (AMGN – Research Report), Treace Medical Concepts (TMCI – Research Report) and Exelixis (EXEL – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amgen (AMGN)
In a report released today, Gregory Renza from Truist Financial maintained a Hold rating on Amgen. The company’s shares closed last Friday at $388.16.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $370.45, representing a -2.3% downside. In a report issued on February 19, Barclays also initiated coverage with a Hold rating on the stock with a $350.00 price target.
See today’s best-performing stocks on TipRanks >>
Treace Medical Concepts (TMCI)
Truist Financial analyst Richard Newitter maintained a Hold rating on Treace Medical Concepts today and set a price target of $2.00. The company’s shares closed last Friday at $1.86.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of
Treace Medical Concepts has an analyst consensus of Hold, with a price target consensus of $3.75, which is a 75.2% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Hold rating on the stock with a $3.00 price target.
Exelixis (EXEL)
Stifel Nicolaus analyst Stephen Willey maintained a Hold rating on Exelixis yesterday. The company’s shares closed last Friday at $44.06.
According to TipRanks.com, Willey is a 4-star analyst with an average return of
Currently, the analyst consensus on Exelixis is a Moderate Buy with an average price target of $46.67, representing a 6.2% upside. In a report issued on February 17, RBC Capital also maintained a Hold rating on the stock with a $46.00 price target.
